Corium International,Inc. (NASDAQ:CORI) Files An 8-K Regulation FD Disclosure

Item7.01.Regulation FD.

On May 11, 2017, Corium International,Inc. (the Company) issued a
press release announcing preliminary positive results from its
recently completed pilot bioequivalence study for Corplex
Donepezil, a once-weekly transdermal therapeutic for Alzheimers
disease.A copy of the press release is furnished as Exhibit 99.1
to this report and is incorporated herein by reference.The
Company will discuss these results further on its second fiscal
quarter earnings conference call scheduled at 8:30 a.m. Eastern
time on May 11, 2017.A copy of the related presentation materials
that the Company intends to provide to investors on the
conference call are furnished as Exhibit 99.2 to this report and
are incorporated herein by reference.These presentation materials
also are posted under the Investors section on the Companys
website at www.coriumgroup.com. The Company does not undertake to
update these presentation materials.

The information furnished with this report, including Exhibit
99.1 and Exhibit 99.2, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference
into any other filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

Item9.01.Financial Statements and Exhibits.

(d)Exhibits.

About Corium International, Inc. (NASDAQ:CORI)

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Corium International, Inc. (NASDAQ:CORI) Recent Trading Information

Corium International, Inc. (NASDAQ:CORI) closed its last trading session up +0.46 at 4.73 with 77,919 shares trading hands.